Friedegund M.
- Country
- Germany
- Department
- Skin Tumor Center
Research Overview
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
- Phase 2 Multicenter Randomized Double-Blind Study of MK-4280A, Pembrolizumab, and Lenvatinib in Patients with Selected Malignant Neoplasms
Data & Insights
Has run more than one trial at 212 of 336 partner sites.
Specializations
Melanoma Research
This investigator specializes in advanced treatments for metastatic melanoma and resectable melanoma, with particular focus on both early-stage and late-stage disease management.
- BRAF V600E/K Mutation Positive Melanoma
- Stage II-IV Melanoma
- Uveal Melanoma
Their research encompasses both adjuvant therapy approaches and treatment strategies for advanced disease states.
Squamous Cell Carcinoma
The investigator conducts research in cutaneous squamous cell carcinoma (cSCC), focusing on novel therapeutic approaches for various stages of the disease.
- Resectable Locally Advanced cSCC
- High-Risk cSCC
- Post-Surgical Treatment Approaches
Their work includes evaluation of immunotherapy treatments and targeted interventions for skin cancer.
Innovative Therapies
The investigator explores cutting-edge therapeutic combinations including immunotherapy agents and targeted treatments for skin cancers.
- Combination Immunotherapy
- Novel Drug Combinations
- Neoadjuvant Treatments
Research includes evaluation of biomarker-based strategies and innovative treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.